ArticleCell2022
SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses.
Article in Cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antibody titers of individuals vaccinated for COVID-19: A systematic review.Journal of biosciences · 2023Pooled it
- Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.Frontiers in immunology · 2022Trial
- Neutralizing Antibody Response Dynamics in COVID-19: Insights from Healthy Vaccinees, Breakthrough Infections, and Critically Ill Patients.Tropical medicine and infectious disease · 2026Article
- Immunological memory to vaccines.Immunity · 2026Review
- Repeated COVID-19 vaccine boosters elicit variant-specific memory B cells in humans.Cell reports · 2026Article
- The computationally designed TRI2-2 miniprotein inhibitor protects against multiple SARS-CoV-2 Omicron variants.Communications biology · 2026Article
- Real-world immune dynamics following COVID-19 vaccination and breakthrough infection: a paired-sample study in Zhejiang Province, China.Frontiers in immunology · 2026Article
- Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platforms.NPJ vaccines · 2025Review
- Dynamic impact of bivalent COVID-19 vaccine boosters on systemic and mucosal antibody and T cell immunity.Scientific reports · 2025Observational
- Repeated COVID-19 vaccine boosters elicit variant-specific memory B cells in humans.bioRxiv : the preprint server for biology · 2025Article
- Bivalent mRNA vaccine booster enhances immunity against XBB.1.5 more effectively than breakthrough infection in K18-hACE2 mice.iScience · 2025Article
- Discovery of novel disulfide-containing PD-1/PD-L1 inhibitor with in vivo influenza therapeutic efficacy.Scientific reports · 2025Article
- Hybrid B- and T-Cell Immunity Associates With Protection Against Breakthrough Infection After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Avon Longitudinal Study of Parents and Children (ALSPAC) Participants.The Journal of infectious diseases · 2025Article
- Article
- Designed miniproteins potently inhibit and protect against MERS-CoV.Cell reports · 2025Article
- SARS-CoV-2 nsp1 mediates broad inhibition of translation in mammals.Cell reports · 2025Article
- Phylogeny-driven design of broadly protective sarbecovirus receptor-binding domain nanoparticle vaccines.bioRxiv : the preprint server for biology · 2025Article
- Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants.Journal of virology · 2025Article
- The omicron variant of SARS-CoV-2 drove broadly increased seroprevalence in a public university setting.PLOS global public health · 2025Article
- Review
84 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
16 authors.
Funding
Abstract
Although infections among vaccinated individuals lead to milder COVID-19 symptoms relative to those in unvaccinated subjects, the specificity and durability of antibody responses elicited by breakthrough cases remain unknown. Here, we demonstrate that breakthrough infections induce serum-binding and -neutralizing antibody responses that are markedly more potent, durable, and resilient to spike mutations observed in variants than those in subjects who received only 2 doses of vaccine. However, we show that breakthrough cases, subjects who were vaccinated after infection, and individuals vaccinated three times have serum-neutralizing activity of comparable magnitude and breadth, indicating that an increased number of exposures to SARS-CoV-2 antigen(s) enhance the quality of antibody responses. Neutralization of SARS-CoV was moderate, however, underscoring the importance of developing vaccines eliciting broad sarbecovirus immunity for pandemic preparedness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.